OVID

Ovid Therapeutics' stock has been impacted by several significant events in the past six months. In November 2025, the company announced a leadership succession plan and reported positive Phase 1 results for OV329, along with an initial closing of approximately $81 million from a private placement. In March 2026, Ovid Therapeutics reported favorable findings from the 7 mg dose cohort of OV329, and announced the expansion of the OV329 program, backed by a $60 million private placement. Additionally, regulatory clearance was received for OV4071 Phase 1 in Australia. These positive developments led to a significant positive market reaction, with shares soaring and price targets being raised by analysts in April 2026.